Symptom severity and exacerbation frequency in medically treated patients with acromegaly. [PDF]
Geer EB +8 more
europepmc +1 more source
Beyond insulin-like growth factor-1 (IGF-1) normalization: portal insulin and hepatic growth hormone (GH) sensitivity across metabolic disease. [PDF]
van AJ +3 more
europepmc +1 more source
Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.
Araujo-Castro M +9 more
europepmc +1 more source
Can acromegaly be controlled in all cases? [PDF]
Chiloiro S +14 more
europepmc +1 more source
Comparison of demographic, clinical and follow-up data of patients with micromegaly and acromegaly: a retrospective analysis from a single tertiary center. [PDF]
Sehit Kara C +6 more
europepmc +1 more source
Cancer risk in acromegaly: reassessing the evidence and impact of biochemical control.
Fleseriu M, Melmed S.
europepmc +1 more source
Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain. [PDF]
Park A +4 more
europepmc +1 more source
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial. [PDF]
Clemmons DR +4 more
europepmc +1 more source
Acromegaly and colorectal cancer risk: emerging roles of the gut microbiota. [PDF]
Grifoni GFA +3 more
europepmc +1 more source

